Strontium [89 Sr] chloride
When ATH:
V10BX01
Characteristic.
Radioisotope means. Sterile, pyrogen free, an aqueous solution of strontium 89 chloride with a pH of 4-7.5, It contains 10,9-22,6 mg / ml substance; radioactive concentration - 37 MBK / mg (1 mCi / ml), the specific activity is 2.96-6.17 Mbq/mg (80-167 MCi / mg) during calibration. Decays with beta radiation with T1/2 - 50,5 days.
Pharmacological action.
Antitumor.
Application.
Palliative treatment of bone pain (as an alternative method or an adjunct to EBRT) individual patients with multiple painful bone metastases in various forms of cancer, incl. for prostate cancer, breast cancer, etc..
Contraindications.
Hypersensitivity.
Restrictions apply.
The very short life of the forecast period (less 3 Months), severe myelosuppression (with platelet counts less than 60,000 / microliter and white blood cell count less than 2400 cells / mm), especially due to prior or concomitant chemo- or radiotherapy; spinal cord compression (due to metastatic lesions), urinary incontinence (if possible catheterization for Radiation Hygiene), urinary tract obstruction, requiring catheterization (while respecting the rules of radiation safety in handling the urine), childhood (Safety and efficacy have not determined).
Pregnancy and breast-feeding.
Use in pregnancy is contraindicated. Adequate and well-controlled studies in human pregnancy have not been conducted. Radioisotope drugs are not recommended for treatment during pregnancy because of the risk exposure of the fetus. Strontium 89 chloride can have a toxic effect on the bone marrow of the fetus. Given the potential effects of radiation on the fetus in the case, when the presence or absence of pregnancy is not established, perform pregnancy tests can prevent unintended pregnancy appointment Sr89.
Women of childbearing age should be warned to avoid pregnancy. Strontium 89 chloride can permeate into breast milk, taking into account the potential risk to the newborn in radiative forcing in the appointment of Sr89 nursing mothers are advised weaning.
Side effects.
Bone marrow suppression, accompanied by thrombocytopenia (unusual bleeding or bruising, black, tarry stools, blood in urine or stool, pinpoint red spots on the skin), and leukopenia (cough or hoarseness, fever or chills, pain in the lower back or side, painful or difficult urination), acute reaction (transient increased pain within 36-72 hours after injection), sensation of heat with the rapid (less 30 from) administered.
Cooperation.
Preparations, causing blood dyscrasia, enhance leukopenia and thrombocytopenia. Preparations, containing calcium, reduce the distribution of matter in the bone minerals, tk. saturation of binding sites in bone calcium can reduce bone seizure Sr89 (calcium supplements should be abolished for 2 Weeks before the administration of strontium). Resume treatment with calcium preparations may approximately 2 weeks after the end of therapy Sr89.
Dosing and Administration.
B /, slowly, for 1-2 min. Momentary, dose 150 MBK (4 mKi), intervals 12 Sun.
Precautions.
Treatment should be carried out in a specialized hospital or outpatient in specialized branch of doctors, training in the use of radioisotope products. Due to the highly radioactive substance checking dosage and general condition of the patient is required prior to administration of the drug. Observe the appropriate safety measures in the personal hygiene of the patient to prevent radioactive contamination of the environment and people, incl. medical staff. The presence of bone metastases should be confirmed with technetium 99m bone scan phosphate (or fosfanatom) before treatment. Increased pain after the introduction stopped by intake of analgesics. Incontinence recommended bladder catheterization. It is recommended to control the formula peripheral blood before and at least 1 times a 2 3-4 weeks to months of therapy.
